Therapy Detail

Therapy Name CVX-241
Therapy Description

CVX-241 is a peptide-antibody fusion protein that targets both Angiopoetin-2 (Ang2) and Vegf, potentially resulted in decreased tumor growth (PMID: 21149738).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
CVX-241 CVX-241 is a peptide-antibody fusion protein that targets both Angiopoetin-2 (Ang2) and Vegf, potentially resulted in decreased tumor growth (PMID: 21149738).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colon adenocarcinoma not applicable CVX-241 Preclinical - Cell line xenograft Actionable In a preclinical study, CVX-241 decreased Ang2 and phosphorylated and total Vegfr2 levels and inhibited tumor growth in a colon adenocarcinoma cell line xenograft model (PMID: 21149738). 21149738
Unknown unknown kidney cancer no benefit CVX-241 Preclinical Actionable In a preclinical study, CVX-241 did not improve overall survival in a mouse model of resected renal cancer (PMID: 27651308). 27651308
Unknown unknown skin carcinoma not applicable CVX-241 Preclinical - Cell line xenograft Actionable In a preclinical study, CVX-241 inhibited tumor growth in a skin carcinoma cell line xenograft model (PMID: 21149738). 21149738
Unknown unknown breast carcinoma not applicable CVX-241 Preclinical - Cell line xenograft Actionable In a preclinical study, CVX-241 inhibited tumor growth in a breast carcinoma cell line xenograft model (PMID: 21149738). 21149738
Unknown unknown breast cancer not applicable CVX-241 Preclinical Actionable In a preclinical study, CVX-241 treatment resulted in improved overall survival in a breast cancer cell line xenograft model and syngeneic mouse model of breast cancer (PMID: 27651308). 27651308
Clinical Trial Phase Therapies Title Recruitment Status